Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs ABRDN Physical Gold Shares ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $288 (market cap $39.89B), while ABRDN Physical Gold Shares ETF trades at $38.06. The key difference: ABRDN Physical Gold Shares ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | SGOL | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $491.22 | $51.41 |
52-Week Low | $278.09 | $31.18 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SGOL, a gold-focused US stock, trades at $39.12, down 0.28% on the day amid a broader bearish technical signal. The stock faces headwinds from declining gold prices, which have fallen over 25% from recent highs, and outflows from gold ETFs as investors react to Federal Reserve policy expectations. Despite this, central bank buying provides underlying support, with entities like Poland and China increasing reserves, highlighting a divergence between speculative selling and long-term institutional demand.
The outlook for SGOL remains cautious near-term due to gold price volatility and hawkish Fed sentiment, but structural support from central bank diversification offers a potential floor. Risks include further ETF liquidations and rising Treasury yields, while opportunities lie in sustained institutional accumulation if macroeconomic uncertainty persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
